Drugmakers agree to halve prices to secure access to China
Astrazeneca, Glaxosmithkline and Novo Nordisk amongst companies to cut drug prices in China.
By Bloomberg News
Drugmakers from Astrazeneca and GlaxoSmithKline to BeiGene Ltd. agreed to cut prices on some of their newest drugs in China by an average of 51% in order to be covered by the country’s national insurance fund.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
